Why Is IOVANCE BIOTHERAPEUT (IOVA) Stock Down Today?
By the Top Tier Newswire AI Desk · October 30, 2026 at 12:05 AM ET · reviewed against 19 wire stories
IOVANCE BIOTHERAPEUT (IOVA) is down -35.45% in the latest session. Our newswire has captured 19 stories on IOVA across 10 sources in the last 36 hours, with AI sentiment reading mixed (avg 46/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Iovance Biotherapeutics shares fell 35.45% to $9.56 on October 29, 2026. The primary driver was the release of updated Phase 2 clinical trial data for its lung cancer treatment, which raised new questions regarding the durability of the therapy.
What Happened
Iovance reported updated Phase 2 IOV-LUN-202 data for previously treated non-small-cell lung cancer on October 29, 2026. The company filed an 8-K with the SEC to disclose these other events and financial statements. While the company discussed positive lifileucel data and a precision TIL strategy, the market reaction was sharply negative. The stock plunged roughly 34% following the release, undercutting its 50-day moving average. The decline was part of a broader tech and biotech selloff, with the Nasdaq likely to end lower on the day.
What The Data Shows
The stock printed 17 fresh 52-week lows and five fresh 52-week highs on October 29, 2026. Over the last eight sessions, the share price moved down 35.1%, declining from $14.86 to $9.65. The company has a market capitalization of $6.6 billion and is currently unprofitable, with a trailing twelve-month EPS of -0.71. Revenue increased 34.5% over the trailing twelve months, but the net margin stands at -89.1%. The stock has a beta of 0.76 and a 52-week range of $1.76 to $15.37. In unusual options activity over the last 36 hours, put premium of $49K significantly outweighed call premium of $8K, with the biggest single print at $49K.
What To Watch
Iovance is scheduled to host a webcast to discuss the positive data for its TIL therapy in metastatic non-small-cell lung cancer. Investors will monitor how the market digests the durability questions raised by the new Phase 2 results.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AI sentiment, last 36h · averaged over 19 stories · 46/100 neutral
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
5h agoStocktwits NewsBEARISH 38General
Dow, S&P 500, Nasdaq Futures Fall As Weak Tech Earnings Trigger Selloff: INTC, IOVA, SLS, AMZN Stocks In Focus
Markets are headed for a mixed close in October, with the Nasdaq likely to end lower, while the Dow and S&P 500 are headed to close in the green.
11h agoTipRanksBULLISH 61Product/PR
Iovance advances precision TIL strategy in lung cancer
Iovance Biotherapeutics ( ($IOVA) ) has issued an announcement. On October 29, 2026, Iovance reported updated Phase 2 IOV-LUN-202 data in previously treated non-squ...
12h agoSEC 8-KNEUTRAL 50General
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) files 8-K
Filed: 2026-10-29 AccNo: 0001104659-26-120261 Size: 233 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
13h agoGuruFocusBEARISH 22Product/PR
Iovance Biotherapeutics (IOVA) Shares Drop 34% After Phase 2 Lung Cancer Trial Results
On October 29, 2026, Iovance Biotherapeutics Inc (NASDAQ: IOVA) saw its stock price plunge roughly 34% following the release of phase 2 clinical trial data for
14h agoSeeking AlphaBEARISH 22Earnings
Iovance plummets on new phase 2 Amtagvi data for non-small-cell lung cancer
Iovance stock sank after phase 2 Amtagvi lung cancer data. Read more here.
15h agoSeeking AlphaBULLISH 63Product/PR
Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer - Slideshow
2026-10-29. The following slide deck was published by Iovance Biotherapeutics, Inc.
17h agoThe FlyBEARISH 12General
Iovance falls -35.4%
17h agoInvestors.comBEARISH 22General
Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer Twist
Iovance stock crashed Thursday, undercutting its 50-day line, on new durability questions for its lung cancer treatment.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →